Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for trea ...

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding ...

To be eligible for the trial, patients must have stage II, IIIA, or IIIB NSCLC and have not achieved pathological complete response after neoadjuvant Keytruda plus chemotherapy and surgical resection.

Patients who received PD-(L)1 inhibitors plus chemotherapy had better progression-free and overall survival than patients who received chemotherapy alone. Results of a meta-analysis suggest that ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...